Use of adrenocorticosteroid hormones in the treatment of multiple sclerosis

References

• Jonsson B, von Reis G, Sahlgren E. Experience of ACTH and cortisone treatment in some organic neurological cases. Acta Psychiatr. Neurol. Scand (Suppl. 74), 60–63 (1951).
   PubMed Web of Science ®Google Scholar
• Miller H, Newell DJ, Ridley A. Multiple sclerosis: Treatment of acute exacerbations with corticotrophin (ACTH). Lancet 2, 1120–1122 (1961).
   PubMed Web of Science ®Google Scholar
• Fog T. The long-term treatment of multiple sclerosis with corticoids. Acta Neurol. Scand 41,473–484 (1965).
   PubMed Web of Science ®Google Scholar
• Miller JHD, Vas CJ, Noronha MJ eta]. Long- term treatment of multiple sclerosis withcorticotropin. Lancet 2,429–431 (1967).
   Google Scholar
• Miller H, Newell DJ, Ridley A. Multiple sclerosis: Trials of maintenance treatment with prednisolone and soluble aspirin. Lancetl, 127–129 (1961).
   Google Scholar
• Merritt HH, Glaser GH, Herrmann C. A study of the short- and long-term effects of adrenal steroids in the clinical patterns of multiple sclerosis. Ann. NY Acad. Sci. 58, 625–632 (1954).
   Google Scholar
• Buckley C, Kennard C, Swash M. Treatment of acute exacerbations of multiple sclerosis with iv. methylprednisolone. j Neurol. Neurosurg. Psychiatry 45, 179–181 (1982).
   PubMed Web of Science ®Google Scholar
• Goas JY, Marion JL, Missoum A. High- dose iv. methylprednisolone in acute exacerbations of multiple sclerosis. J. NeuroL Neurosurg. Psychiatry46, 99 (1983).
   PubMedGoogle Scholar
• Thompson AJ, Kennard C, Swash M et al. Relative efficacy of iv. methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology39,969–971 (1989).
   Google Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. NeuroL Neurosurg. Psychiatry50,511–516 (1987).
   Google Scholar
• Barnes D, Hughes RA, Morris RW et al. Randomised trial of oral and iv. methylprednisolone in acute relapses of multiple sclerosis. Lancet 29,349(9056), 902–906 (1997).
   Google Scholar
• Goodkin DE, Kinkel RP, Weinstock-Guttman B et al. A Phase II study of iv. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51 239–245 (1998).
   Google Scholar
• Zivadinov R, Rudick R, De Masi et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology57, 1239–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Fauci AS, Dale DC, Balow JE. Gluco corticosteroid therapy: mechanisms of action and clinical consideration. Ann. Intern. Med. 84,304-315 (1976).
   Google Scholar
• Leussink V, Jung S, Merschdorf U, Toyka K, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol 58,91–97 (2001).
   Google Scholar
• Buttergereit F, Burmester G, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunology Today21, 192–199 (2000).
   PubMedGoogle Scholar
• Crockard AD, Treacy MT, Droogan AG, McNeill TA, Hawkins SA. Transient immunomodulation by iv. methylprednisolone treatment of multiple sclerosis. Multiple Sclerosis 1,20–24 (1995).
   Google Scholar
• Wandinger KP, Wessel K, Trillenberg P, Heindl N, Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neur. Scand. 97,359–365 (1998).
   Google Scholar
• Ossege LM, Sindern E, Voxx B, Malin J. Corticosteriods induce expression of transforming growth factor betal mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis. J Neuroimmunology84, 1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. Neuroimmunology85, 122–130 (1998).
   PubMed Web of Science ®Google Scholar
• Baumhueter S, Singer MS, Henzel W et al. Binding of L-selectin to the vascular sialomucin CD34. Science 262,436–438 (1993).
   PubMed Web of Science ®Google Scholar
• Elovaara I, Lalla M, Pare E, Lehtimaki T, Dastidar P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 51,1703–1708 (1998).
   Google Scholar
• Droogan AG, Crockard AD, McMillan SA, Hawkins SA. Effects of iv. methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology50,224–229 (1998).
   Google Scholar
• Lujan S, Masjuan J, Roldan E, Villar LM, Gonzalez-Porque P, Alvarez-Cermeno JC. The expression of integrins on activated T-cells in multiple sclerosis. Effect of iv. methylprednisolone treatment. Multiple Sclerosis 4,239–242 (1998).
   Google Scholar
• Cronstein BN, Kimmel SC, Levin RI et al. A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl Acad. ScL USA 89,9991–9995 (1992).
   Google Scholar
• Melcangi RC, Cavarretta I, Magnaghi V, Ciusani E, Salmagg A. Corticosteroids protect oligodendrocytes from cytokine-induces cell death. NeuroReportll (18), 3969–3972 (2000).
   Google Scholar
• Ruiz P, Gomez F, King M, Lopez R, Darby C, Schreiber AD. In vivo glucocorticoid modulation of pig splenic macrophage Fc gamma receptors. j Clin. Invert. 88,149–157 (1991).
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Dencoff JE, Correa NJ et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46, 1626–1632 (1996).
   PubMed Web of Science ®Google Scholar
• Keles M, Seyithan T, Aksoy H, Sen N, Polat R, Akcay E The effect of corticosteroids on serum and cerebrospinal fluid nitric oxide levels in multiple sclerosis. Clin. Chem. Med. 39(9), 827–829 (2001).
   Google Scholar
• Trotter JL, Garvey WE Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology30,702–708 (1980).
   PubMed Web of Science ®Google Scholar
• Goodin D. Perils and pitfalls in the interpretation of clinical trials: A reflection on the recent experience in multiple sclerosis. Neuroepidemiology18,53–63 (1999).
   PubMed Web of Science ®Google Scholar
• Rose AS, Kuzme JW, Kurtzke JF et al. Co- operative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo. Final report. Neurology20,1–59 (1970).
   Google Scholar
• Barnes MP, Batemen DE, Cleland PG et al. Intravenous methylprednisolone for multiple sclerosis in relapse. j NeuroL Neurosurg. Psychiatry 48,157–159 (1985).
   PubMed Web of Science ®Google Scholar
• Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology54,2039–2044 (2000).
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Gandolfo C, Loeb C. 'Bolus' methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital. NeuroL ScL 4,169–172 (1983).
   Google Scholar
• Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology51, 529–534 (1998).
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl. j Med 329, 1764–1769 (1993).
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Schaldemose N, Frederiksen JL, Olesen J. A randomozed, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology52,1479–1484 (1999).
   PubMed Web of Science ®Google Scholar
• Katz D, Taubenberger JK, Cannella B et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. NeuroL 34,661–669 (1993).
   PubMed Web of Science ®Google Scholar
• Thorpe JVV, Kidd D, Mosley IF et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology46, 373–378 (1996).
   PubMed Web of Science ®Google Scholar
• Jeffery DR. Dose response relationships and relation to disease activity in multiple sclerosis. j Neurol. Sci. 178,2–9 (2000).
   PubMed Web of Science ®Google Scholar
• Katz D et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. 34,661–669 (1993).
   PubMed Web of Science ®Google Scholar
• Bruck W et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 42, 783–793 (1997).
   PubMed Web of Science ®Google Scholar
• Nesbit GM et al. Multiple Sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and three at autopsy. Radiology 180,467–474 (1991).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl. j Med. 338(5), 278–285 (1998).
   Google Scholar
• Thompson AJ, Miller D, Youl B et al. Serial gadolinium-enhanced MRI in relapsing/ remitting multiple sclerosis of varying disease duration. Neurology42,60–63 (1992).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Silver NC, Good CD, Miller DH, Thompson EJ. Immunological time-course of gadolinium-enhanced MRI lesions in patients with multiple sclerosis. Eur. Neurol. 44,222–228 (2000).
   Google Scholar
• Matthews WB, Acheson ED, Batchelor JR, Weller RO. Course and prognosis. McAlpine .'s Multiple Sclerosis 4,49–72 (1985).
   Google Scholar
• Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with iv. therapy equivalent dose. j Neurol. Neurosurg. Psychiatry 56,1219–1220 (1993).
   PubMed Web of Science ®Google Scholar
• LaMantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Toni V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapes. Eur. Neurol. 34,199–203 (1994).
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Valentino P, Russo C et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50, 1833–1836 (1998).
   PubMed Web of Science ®Google Scholar
• Gasperini C, Pozzilli C, Bastianello S et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon la treatment in relapsing remitting multiple sclerosis. Neurology 50, 403–406 (1998).
   PubMed Web of Science ®Google Scholar
• Miller DH, Weinstock-Gutman B, Bethoux F et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Multiple Sclerosis 6,267–273 (2000).
   PubMed Web of Science ®Google Scholar
• Gasperini C, Pozzilli C, Bastianello S et al. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Ada Neurol. Scand. 95, 201–207 (1997).
   PubMed Web of Science ®Google Scholar
• Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. j Neurol. Neurosurg. Psychriatry 62,112–118 (1997).
   PubMed Web of Science ®Google Scholar
• Wolinsky JS. MRI aspects of secondary progressive multiple sclerosis. Multiple Sclerosis 8,85–87 (2002).
   PubMedGoogle Scholar
• Bergamaschi R, Versino M, Railola E, Citterio A, Cosi V High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up. Acta Neurol. (Napoli) 15(1), 33–43 (1993).
   Google Scholar
• Gaillard P, Van der Meide PH, de Boer A, Breimer DD. Glucocorticoid and typel interferon interactions at the blood-brain barrier; relevance for drug therapies for multiple sclerosis. NeuroReport 12(10), 2189–2193 (2001).
   PubMed Web of Science ®Google Scholar